Abstract:The emergence of drug resistant variants of the influenza virus has led to a great need to identify novel and effective antiviral agents. In our previous study, a series of sialic acid (C-2 and C-4)-pentacyclic triterpene conjugates have been synthesized, and a five-fold more potent antiviral activity was observed when sialic acid was conjugated with pentacyclic triterpene via C-4 than C-2. It was here that we further reported the synthesis and anti-influenza activity of novel sialic acid (C-5 and C-9)-pentacyclic triterpene conjugates. Their structures were confirmed by ESI-HRMS, ¹H-NMR, and 13C-NMR spectroscopic analyses. Two conjugates (26 and 42) showed strong cytotoxicity to MDCK cells in the CellTiter-Glo assay at a concentration of 100 μM. However, they showed no significant cytotoxicity to HL-60, Hela, and A549 cell lines in MTT assay under the concentration of 10 μM (except compound 42 showed weak cytotoxicity to HL-60 cell line (10 μM, ~53%)). Compounds 20, 28, 36, and 44 displayed weak potency to influenza A/WSN/33 (H1N1) virus (100 μM, ~20-30%), and no significant anti-influenza activity was found for the other conjugates. The data suggested that both the C-5 acetylamide and C-9 hydroxy of sialic acid were important for its binding with hemagglutinin during viral entry into host cells, while C-4 and C-2 hydroxy were not critical for the binding process and could be replaced with hydrophobic moieties. The research presented herein had significant implications for the design of novel antiviral inhibitors based on a sialic acid scaffold.

Design, Synthesis and Biological Evaluation of Pentacyclic Triterpene Dimers as HCV Entry Inhibitors

Synthesis and biological evaluation of novel pentacyclic triterpene α-cyclodextrin conjugates as HCV entry inhibitors

Synthesis and Anti‐HCV Entry Activity Studies of Β‐cyclodextrin–pentacyclic Triterpene Conjugates

Development of Bivalent Oleanane-Type Triterpenes As Potent HCV Entry Inhibitors.

Discovery of 5-Alkyl-2-pyrazol-oxazolidin-4-one Derivatives As Novel Hepatitis B Virus Capsid Assembly Modulators

Synthesis and biological evaluation of ring A and/or C expansion and opening echinocystic acid derivatives for anti-HCV entry inhibitors

Synthesis and Biological Evaluation of Echinocystic Acid Derivatives As HCV Entry Inhibitors

Design, Synthesis and Biological Evaluation of N,N-3-phenyl-3-benzylaminopropanamide Derivatives As Novel Cholesteryl Ester Transfer Protein Inhibitor

Development Of Oleanane-Type Triterpenes As A New Class Of Hcv Entry Inhibitors

Discovery of Novel N,N-3-phenyl-3-benzylaminopropionanilides As Potent Inhibitors of Cholesteryl Ester Transfer Protein in Vivo.

Elucidation of the Pharmacophore of Echinocystic Acid, a New Lead for Blocking HCV Entry.

Synthesis and evaluation of pentacyclic triterpenoids conjugates as novel HBV entry inhibitors targeting NTCP receptor

Structure-activity Relationships of Cryptopleurine Analogs with E-ring Modifications As Anti-Hepatitis C Virus Agents.

Design and synthesis of HCV agents with sequential triple inhibitory potentials

Discovering novel anti-HCV compounds with inhibitory activities toward HCV NS3/4A protease

Flavonoid-triazolyl hybrids as potential anti-hepatitis C virus agents: Synthesis and biological evaluation

Design, Synthesis And Biological Activity Evaluation Of Novel Conjugated Sialic Acid And Pentacyclic Triterpene Derivatives As Anti-Influenza Entry Inhibitors

Design, Synthesis, and Biological Evaluation of Novel Piperidine-4-carboxamide Derivatives As Potent CCR5 Inhibitors

Tetrazole and Triazole As Bioisosteres of Carboxylic Acid: Discovery of Diketo Tetrazoles and Diketo Triazoles As Anti-Hcv Agents.

Synthesis and In Vitro Anti-Influenza Virus Evaluation of Novel Sialic Acid (C-5 and C-9)-Pentacyclic Triterpene Derivatives

Synthesis of Novel Pentacyclic Triterpene-Neu5ac2en Derivatives and Investigation of Their in Vitro Anti-Influenza Entry Activity.